Alpha Teknova (TKNO) Sidoti Micro-Cap Virtual Conference summary

Company overview and strategy

• Specializes in custom reagents for life sciences, serving therapeutics, diagnostics, and tools companies.

• Differentiates through fast turnaround and ability to produce small, custom batches for both research and GMP clinical use.

• Growth strategy includes expanding manufacturing, building a commercial team, and developing proprietary products.

• Recently invested $40 million in a new ISO 13485-certified facility to support custom manufacturing.

• Broad customer base of 2,500, with 23% of revenue from cell and gene therapy clients.

Product portfolio and customer journey

• Offers pre-poured agar plates, microbial culture media, buffers/reagents, and proprietary products.

• Supports customers from early research (catalog products) to clinical and commercial stages (custom and GMP products).

• Customers ordering custom products spend 19x more, and GMP customers spend 62x more than catalog-only buyers.

• Sweet spot is 100–1,000 liter batch sizes, ideal for cell and gene therapy clients.

• Number of Clinical Solutions (GMP) customers grew from 13 to 43 in three years.

Market trends and financial outlook

• Biotech funding rebounded in Q1 and Q2 after two tough years, with a typical four-quarter lag before impacting revenue.

• Projecting flat year-on-year revenue for the current year, but signs of increased activity and future growth.

• Research/lab essentials make up ~80% of revenue, with higher margins on clinical/GMP products (60–80% vs. 40–60%).

• Raised $15 million to bridge to cash flow positive; expects adjusted EBITDA breakeven at $50–$55 million annualized revenue.

• High fixed cost base allows for strong profit drop-through as revenue grows, with cash flow positive expected shortly after EBITDA breakeven.